



Calithera Announces Multiple Abstracts Selected for Presentation at the 57th American Society of Hematology Annual Meeting

November 5, 2015

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), announced today that four abstracts highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor for the treatment of hematological malignancies, have been selected for presentation at the 57th American Society of Hematology (ASH) annual meeting and exposition, taking place December 5-8, 2015, in Orlando, Florida. Details for the presentations are as follows:

Metabolomic, Proteomic and Genomic Profiling Identifies Biomarkers of Sensitivity to Glutaminase

Abstract #1802

Andrew L. MacKinnon, Ph.D., Calithera Biosciences

Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

Saturday, December 5, 2015 at 5:30-7:30 PM ET

Orange County Convention Center, Hall A

Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML

Abstract #2559

Juliana Velez Lujan, Ph.D., University of Texas MD Anderson Cancer Center

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Sunday, December 6, 2015 at 6:00-8:00 PM ET

Orange County Convention Center, Hall A

Phase I Study of CB-839, a First-in-class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients With Relapsed/ Refractory Leukemia

Abstract #2566

Eunice S. Wang, M.D., Roswell Park Cancer Institute

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Sunday, December 6, 2015 at 6:00-8:00 PM ET

Orange County Convention Center, Hall A

Phase I Study of CB-839, a First-in-class, Glutaminase Inhibitor in Patients With Multiple Myeloma and Lymphoma

Abstract #3059

Dan Vogl, M.D., University of Pennsylvania

Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Sunday, December 6, 2015 at 6:00-8:00 PM ET

Orange County Convention Center, Hall A

The meeting abstracts can be viewed online through the ASH website at www.hematology.org.

About Calithera Biosciences

Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body's cancer-fighting immune cells, known as cytotoxic T-cells. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.

CONTACT:

Jennifer McNealey

ir@Calithera.com

650-870-1071



Calithera Biosciences, Inc.